Silo Pharma Inc. is a biopharmaceutical company focused on merging traditional therapies with psychedelic research to develop novel treatments for various mental health disorders and rare diseases. By leveraging its proprietary drug delivery platforms and strategic collaborations, Silo aims to advance the clinical application of psychedelics in a regulatory-compliant manner. With a robust pipeline and a commitment to innovation, the company is positioned to address significant unmet medical needs while contributing to the evolving landscape of mental health therapeutics. Silo Pharma seeks to create value for investors through responsible development and market engagement in this burgeoning field.
| Revenue (TTM) | 72,100 |
| Gross Profit (TTM) | 8,580 |
| EBITDA | $-4.77M |
| Operating Margin | -8846.00% |
| Return on Equity | -99.90% |
| Return on Assets | -46.30% |
| Revenue/Share (TTM) | $0.10 |
| Book Value | $5.24 |
| Price-to-Book | 1.18 |
| Price-to-Sales (TTM) | 88.60 |
| EV/Revenue | 5.93 |
| EV/EBITDA | 0.56 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $1.13M |
| Float | $1.06M |
| % Insiders | 18.21% |
| % Institutions | 6.24% |
Volatility is currently contracting
NVIDIA developer program resources expected to support autonomous AI agent innovation and marketing NVIDIA developer program resources expected to support autonomous AI agent innovation and marketing
Study designed to evaluate performance and formulation stability of proprietary nose-to-brain delivery system
Positive data supports the continued advancement of FDA Investigational New Drug (IND)- enabling development program SARASOTA, FLA., June 23, 2026 (GLOBE NEWSWIRE) -- Silo Pharma (Nasdaq: SILO) (“Silo” or “the Company”), a developmental-stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced that it has confirmed the physical, chemical and microbiological stability of its investigational soft-mist intranasal prophylactic, SPC-15, through nine months of real-time testing.
SARASOTA, FLA., June 18, 2026 (GLOBE NEWSWIRE) -- Silo Pharma (Nasdaq: SILO) (“Silo” or “the Company”), a developmental-stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced that it received confirmation from the Listing Qualifications Department of The Nasdaq Stock Market LLC informing the Company that, as of June 17, 2026, it has regained compliance with the minimum closing bid price requirement under Nasdaq Listing Rule 5550(a)(2). Silo's common stock continues to trade on the Nasdaq Capital Market, and the matter is now closed.
Federal initiatives focused on PTSD and related conditions appears to validate need for new and novel approaches to mental health treatment
Launch of Dedicated AI Subsidiary Positions Company for New Revenue Streams While Advancing PTSD Program Toward Phase 1 SARASOTA, FL, April 22, 2026 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or “the Company), a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company, today announced a strategic business expansion into AI technology as a second line of business resulting from its recent purchase of the assets of Qwikagents.ai, an AI platform designed to support the deployment of autonomous AI agents. “We expect that Silo's diversification into AI infrastructure will enable it to take advantage of opportunities in high-growth, transformative technologies that we believe are driving the current tech economy,” said Eric Weisblum, Chief Executive Officer.
